SUPRANE Drug Patent Profile

When do Suprane patents expire, and when can generic versions of Suprane launch?

Suprane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in SUPRANE is desflurane. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the desflurane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suprane

A generic version of SUPRANE was approved as desflurane by SHANGHAI HENGRUI on February 26^th, 2018.

Summary for SUPRANE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	35
Patent Applications:	2,950
Drug Prices:	Drug price information for SUPRANE
What excipients (inactive ingredients) are in SUPRANE?	SUPRANE excipients list
DailyMed Link:	SUPRANE at DailyMed

See drug prices for SUPRANE

Recent Clinical Trials for SUPRANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute, Egypt	N/A
Sefako Makgatho Health Sciences University	N/A
GAMZE PİRİNÇ ŞAŞIOĞLU	N/A

See all SUPRANE clinical trials

Pharmacology for SUPRANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Paragraph IV (Patent) Challenges for SUPRANE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUPRANE	Inhalation	desflurane	99.9%	020118	1	2008-09-11

US Patents and Regulatory Information for SUPRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	AN	RX	Yes	Yes

Expired US Patents for SUPRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	4,762,856*PED
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	5,617,906*PED

International Patents for SUPRANE

See the table below for patents covering SUPRANE around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	880434
Greece	3026680
Netherlands	950021
Spain	2113423
Mexico	9203092	COMPOSICION ANESTESICA Y METODO PARA SU USO.
Germany	69224823

Supplementary Protection Certificates for SUPRANE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0285237	94C0006	France		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0285237	95C0008	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: SUPRANE

Last updated: July 28, 2025

Introduction

SUPRANE, known generically as desflurane, is a volatile anesthetic agent widely used in hospital settings for the induction and maintenance of general anesthesia. Developed by Baxter International, now under the pharmaceutical giant Beckman Coulter, SUPRANE’s market position hinges on its unique pharmacokinetic profile, regulatory environment, competitive landscape, and evolving healthcare practices. This analysis explores the multifaceted market dynamics influencing SUPRANE’s trajectory and projects its financial outlook amid changing healthcare trends.

Pharmacological Profile and Clinical Preference

Supra-volatile, achieving rapid induction and emergence, SUPRANE is valued in anesthesiology for its low blood-gas partition coefficient, enabling swift adjustments during surgery. Its minimal cardiac and respiratory depression appeal to anesthesiologists; however, its propensity to cause airway irritation limits universal adoption. These pharmacological characteristics influence purchasing decisions and, consequently, market demand.

Market Size and Segmentation

Globally, the anesthesia market was valued at approximately USD 4.9 billion in 2022, with inhalational agents like desflurane accounting for a significant, though decreasing, share due to rising popularity of total intravenous anesthesia (TIVA) techniques. Within this landscape, SUPRANE commands a niche among high-income healthcare markets, especially in North America and Europe, where technological sophistication and physician preferences favor inhalational agents with rapid onset and emergence features.

Regulatory Environment and Market Access

Supra-volatile anesthetics are scrutinized for environmental impact; desflurane’s high global warming potential (GWP) has led to regulatory advisories and calls for environmental sustainability in anesthesia practices. The European Union’s increased focus on climate impact has prompted restrictions and encouragements toward low-GWP agents, pressuring SUPRANE’s market expansion within Europe. Conversely, in the U.S., regulatory approval modifications and safety updates influence supply chain and usage restrictions.

Competitive Landscape

The anesthesia agent market is characterized by intense competition primarily between desflurane (SUPRANE), sevoflurane, and isoflurane. Sevoflurane, with lower GWP and comparable efficacy, has gained market share, especially in outpatient settings. New entrants and non-inhalational alternatives like TIVA pose long-term threats. Key competitors' pricing strategies, formulation innovations, and environmental policies impact SUPRANE’s market share and profitability.

Market Drivers

• Technological Advancements: Anesthetic delivery systems with precision dosing enhance SUPRANE’s appeal.
• Rapid Recovery Needs: Surgements in outpatient and ambulatory surgeries emphasize agents with quick emergence profiles.
• Aging Populations: An increase in surgeries among elderly enhances demand for reliable anesthetic options.
• Hospital Protocols: Adoption of protocols favoring inhalational anesthesia supports sustained demand amid evolving clinical practices.

Market Challenges

• Environmental Concerns: SUPRANE’s high GWP (~2540 CO₂ equivalents) hinders adoption in environmentally conscious markets.
• Cost Considerations: Suprafleun’s higher acquisition cost compared to sevoflurane restricts use where cost-effectiveness guides decision-making.
• Preference Shift: Rising TIVA utilization reduces inhalational agent reliance, especially in settings adopting total intravenous anesthesia.

Financial Trajectory and Revenue Outlook

Historical Revenue Trends
As a premium inhalational agent, SUPRANE historically generated high margins due to its specialized pharmacokinetics and brand loyalty. However, recent years have exhibited revenue stagnation or slight declines in certain markets, aligning with market saturation, environmental restrictions, and competitive pressures.

Forecasting Future Revenue
Analysts project a compounded annual growth rate (CAGR) of approximately 1-2% for SUPRANE through 2030, influenced by incremental adoption in emerging markets and hospitals prioritizing rapid surgical turnover. Nonetheless, the trajectory may be moderated by environmental regulations and the shift toward alternative anesthetic modalities.

Impact of Environmental Policies
Regulatory trends favor low-GWP agents; for SUPRANE, increased operating costs and potential restrictions could suppress revenue growth. Companies are investing in sustainable alternatives; for instance, desflurane's environmental footprint is under scrutiny, which may lead to phased reductions in usage or formulation modifications.

Market Expansion Opportunities
Emerging markets with expanding healthcare infrastructure offer growth potential, particularly where regulatory frameworks are less restrictive. Additionally, innovations in delivery systems, such as portable anesthesia machines, could stimulate demand.

Strategic Initiatives
To sustain financial performance, stakeholders are contemplating portfolio diversification into lower-GWP inhalational agents, investment in environmental impact mitigation, and education initiatives to reinforce SUPRANE’s clinical benefits. Mergers or collaborations may also shape future market positioning.

Conclusion

SUPRANE’s current and future market dynamics are intricately linked to its pharmacological merits, regulatory climate, environmental considerations, and competitive forces. While its high efficacy and rapid recovery profile sustain niche demand, sustainability concerns and evolving clinical standards pose challenges. Its financial trajectory will hinge on strategic adaptation to these forces, balancing innovation with regulatory compliance and market preferences.

---

Key Takeaways

• SUPRANE’s success depends on balancing its clinical advantages against environmental and cost-related challenges.
• Regulatory shifts favoring low-GWP anesthetics could limit SUPRANE’s market growth in mature regions.
• Emerging markets provide growth opportunities, especially with infrastructure expansion and less restrictive policies.
• Innovative delivery systems and environmental mitigation strategies are essential for market sustainability.
• Sector players must monitor evolving clinician preferences, regulatory landscapes, and environmental policies to optimize revenue streams.

---

FAQs

1. What factors influence SUPRANE’s market share compared to other inhalational anesthetics?
Clinicians prioritize rapid induction and emergence, which favor SUPRANE, but environmental concerns and costs favor alternatives like sevoflurane. Regulatory restrictions and physician preferences significantly influence market share shifts.

2. How does environmental regulation impact SUPRANE’s future profitability?
Stringent policies aimed at reducing global warming potential could restrict SUPRANE’s use, increase compliance costs, and accelerate the adoption of environmentally friendly alternatives, pressuring profitability.

3. Are there innovations that could enhance SUPRANE’s market resilience?
Yes, developing formulations with lower GWP, investing in environmentally sustainable delivery systems, and positioning as an elite anesthetic for specific surgical contexts could bolster resilience.

4. What role do emerging markets play in SUPRANE’s long-term outlook?
Emerging markets represent growth opportunities due to increasing healthcare access and less restrictive environmental policies, providing avenues to expand sales and offset stagnations elsewhere.

5. How will the shift towards TIVA affect SUPRANE’s market trajectory?
The rising preference for TIVA reduces reliance on inhalational agents; however, SUPRANE remains relevant in hospitals requiring rapid anesthetic adjustments, maintaining a finite but significant role.

---

Sources

1. Global Inhalational Anesthetics Market Report, 2022.
2. Environmental Impact of Desflurane, European Medicines Agency, 2021.
3. Trends in Anesthesia Practice, American Society of Anesthesiologists, 2023.
4. MarketPro Reports: Anesthesia Agents Industry Forecast, 2023-2030.
5. Healthcare Infrastructure and Economic Development in Emerging Markets, WHO, 2022.